Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?

AIDS. 2013 Jan 2;27(1):141-4. doi: 10.1097/QAD.0b013e328358fcc2.

Abstract

We report long-term virologic response to etravirine and tenofovir/emtricitabine in four HIV-1-infected patients who had prior standard genotypic resistance testing showing an isolated K103N mutation (three acquired, one transmitted). In three patients tested, the K103N mutation was detected in cellular HIV-1 DNA whereas remaining suppressed on etravirine plus tenofovir/emtricitabine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • Asparagine
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Drug Resistance, Multiple, Viral / drug effects
  • Drug Resistance, Multiple, Viral / genetics
  • Drug Therapy, Combination
  • Emtricitabine
  • Female
  • Genotype
  • HIV Seropositivity / drug therapy*
  • HIV Seropositivity / genetics
  • HIV-1 / drug effects
  • HIV-1 / genetics*
  • Humans
  • Lysine
  • Male
  • Mutation*
  • Nitriles
  • Organophosphonates / administration & dosage
  • Organophosphonates / therapeutic use*
  • Pyridazines / administration & dosage
  • Pyridazines / therapeutic use*
  • Pyrimidines
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Tenofovir

Substances

  • Anti-HIV Agents
  • Nitriles
  • Organophosphonates
  • Pyridazines
  • Pyrimidines
  • Reverse Transcriptase Inhibitors
  • etravirine
  • Deoxycytidine
  • Asparagine
  • Tenofovir
  • Emtricitabine
  • Adenine
  • Lysine